ClinicalTrials.gg
CompletedNCT00517634Updated Dec 16, 2016Results posted

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

A Phase 4 interventional study of FP and SFC in Asthma, sponsored by GlaxoSmithKline. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
117th of 146
23 · median 100
Started
2007
with 17 others
Phase 4
52 of 147
1 open now
Registered
42nd of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 117th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 42nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is influenced by the time of allergen challenge relative to the time of dosing.

Read the detailed description

A 12-week, randomised, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate, fluticasone propionate and placebo on perpheral blood eosinophils and serum IL-5 in response to allergen challenge in asthma subjects when allergen challenge is administered at 1 hour or 11-12 hours post-dose of the dosing interval

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • allergen challenge
  • IL-5
  • eosinophils
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • .
  • Outpatient.
  • Male or non-pregnant/non-lactating female.
  • Aged 18-55.
  • Diagnosis of asthma.
  • Pre-bronchodilatory > 75% predicted.
  • Using inhaled short-acting beta-2-agonists (SABA) with no inhaled .
  • Judged capable of withholding SABA for at least 6 hours prior to visits.
  • Reversibility of >12% and 200mL or PC20 of \<8mg/mL.
  • Demonstration of atopy

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma.
  • Use of proscribed asthma medications.
  • Use of anti-histamines or potent inhibitors of .
  • Respiratory tract infection.
  • Asthma exacerbation with 4 weeks of Visit 1.
  • Subjects with exercise induced asthma only.
  • Concurrent respiratory disease.
  • Other , uncontrolled condition or disease.
  • Use of any drug within 30 days.
  • Allergic to beta-2-agonists, inhaled or .
  • Positive pregnancy test.
  • Using medications.
  • Milk protein allergy.
  • Factors likely to interfere with attendance.
  • Current smokers or ex-smokers with a history of >10 pack years.
  • Affiliation wih Investigator site.
  • Medications that may affect the course of asthma or interact with sympathomimetic amines.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Sequence 1: FP, SFC, Placebo

    Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

  • Experimental
    Sequence 2: Placebo, SFC, FP

    Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

  • Experimental
    Sequence 3: SFC, FP, Placebo

    Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

  • Experimental
    Sequence 4: SFC, Placebo, FP

    Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

  • Experimental
    Sequence 5: FP, Placebo, SFC

    Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

  • Experimental
    Sequence 6: Placebo, FP, SFC

    Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period

    Drug: FP · Drug: SFC · Drug: Placebo

Interventions

  • DrugFP

    Fluticasone Propionate 100 mcg BD

  • DrugSFC

    Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35

    Number of peripheral blood eosinophils measured from blood draws

    Time frame: 0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35

Secondary outcomes

  1. Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14

    Number of peripheral blood eosinophils measured from blood draws

    Time frame: 0-6 hours, post allergen challenge, 1 hour post treatment, Day 14

  2. Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35

    Amount of serum interleukin (IL)-5 measured from blood draws

    Time frame: 0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35

  3. Weighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14

    Amount of serum IL-5 measured from blood draws

    Time frame: 0-6 hours post allergen challenge, 1 hour after dosing, Day 14

07

Results

Posted Sep 2, 2009

Participant flow

First Treatment Period
Participant flow — First Treatment Period
MilestoneSequence 1: FP, SFC, PlaceboSequence 2: Placebo, SFC, FPSequence 3: SFC, FP, PlaceboSequence 4: SFC, Placebo, FPSequence 5: FP, Placebo, SFCSequence 6: Placebo, FP, SFC
Started444344
Completed444344
Not completed000000
Second Treatment Period
Participant flow — Second Treatment Period
MilestoneSequence 1: FP, SFC, PlaceboSequence 2: Placebo, SFC, FPSequence 3: SFC, FP, PlaceboSequence 4: SFC, Placebo, FPSequence 5: FP, Placebo, SFCSequence 6: Placebo, FP, SFC
Started444344
Completed444334
Not completed000010
Withdrew: Withdrawal by subject000010
Third Treatment Period
Participant flow — Third Treatment Period
MilestoneSequence 1: FP, SFC, PlaceboSequence 2: Placebo, SFC, FPSequence 3: SFC, FP, PlaceboSequence 4: SFC, Placebo, FPSequence 5: FP, Placebo, SFCSequence 6: Placebo, FP, SFC
Started444334
Completed444334
Not completed000000

Outcome measures

PrimaryWeighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35

Number of peripheral blood eosinophils measured from blood draws

Time frame:
0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35
Reported as:
Mean · Giga Units per Liter (GI/L)
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35
Giga Units per Liter (GI/L)PlaceboFP 100 mcg BIDSFC 50/100 mcg BID
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35-0.050 (-0.072 to -0.029)-0.040 (-0.061 to -0.019)-0.023 (-0.044 to -0.001)
SecondaryWeighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14

Number of peripheral blood eosinophils measured from blood draws

Time frame:
0-6 hours, post allergen challenge, 1 hour post treatment, Day 14
Reported as:
Mean · Giga Units per Liter (GI/L)
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14
Giga Units per Liter (GI/L)PlaceboFP 100 mcg BIDSFC 50/100 mcg BID
Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 14-0.023 (-0.039 to -0.006)-0.022 (-0.038 to -0.007)-0.013 (-0.029 to -0.004)
SecondaryWeighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 35

Amount of serum interleukin (IL)-5 measured from blood draws

Time frame:
0-6 hours post allergen challenge, 10-11 hours post treatment, Day 35

Results for this outcome have not been posted.

SecondaryWeighted Mean Change From Baseline Over 0-6 Hours in Serum IL-5 Post-Allergen Challenge on Day 14

Amount of serum IL-5 measured from blood draws

Time frame:
0-6 hours post allergen challenge, 1 hour after dosing, Day 14

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/22 (0%)14/22 (63.6%)
FP 100 mcg BID—0/23 (0%)16/23 (69.6%)
SFC 50/100 BID—1/22 (4.5%)10/22 (45.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboFP 100 mcg BIDSFC 50/100 BID
AppendicitisInfections and infestations0/220/231/22
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboFP 100 mcg BIDSFC 50/100 BID
HeadacheNervous system disorders7/223/232/22
NasopharyngitisInfections and infestations2/223/232/22
Pharyngolarngeal PainRespiratory, thoracic and mediastinal disorders1/222/232/22
Throat irritationRespiratory, thoracic and mediastinal disorders1/222/230/22
DiarrheaGastrointestinal disorders1/221/230/22
Dry ThroatRespiratory, thoracic and mediastinal disorders0/221/231/22
HypersensitivityImmune system disorders0/221/231/22
NauseaGastrointestinal disorders1/221/230/22
Productive coughRespiratory, thoracic and mediastinal disorders0/221/231/22
RhinorrheaRespiratory, thoracic and mediastinal disorders1/220/231/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study Population
Mean36.6 ± 6.63
Gender
Gender(Participants)Overall Study Population
Female9
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Overall Study Population
African American2
Caucasian21
08

Study locations

2 sites
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2007
First posted
Aug 17, 2007
Start
Aug 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Sep 2, 2009
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00517634
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 17, 2007
Start date
Aug 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Sep 2, 2009
Last update
Dec 16, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion